WST VP gets PSU shares, withholds stock for taxes

West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters reported equity-related transactions involving company common stock.

Rhea-AI Filing Summary

West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters reported equity-related transactions involving company common stock. On February 17, 2026, he acquired 149.684 shares at a price of $0.00 per share as a grant or award. A footnote explains these shares resulted from performance stock units for the 2023–2025 performance period that vested and became payable on that date.

On the same date, Winters disposed of 50.579 shares at $243.19 per share to cover tax liabilities through share withholding, rather than an open-market sale. After these transactions, he directly owned 1,462.103 common shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Winters Chad

Role VP, Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	149.684	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	50.579	$243.19	$12K

Holdings After Transaction: Common Stock — 1,462.103 shares (Direct)

Footnotes (1)

1. F1. These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did WST executive Chad Winters report on this Form 4?

Chad Winters, VP and Chief Accounting Officer of West Pharmaceutical Services (WST), reported receiving 149.684 common shares from vested performance stock units and a related 50.579-share disposition for taxes. Both transactions occurred on February 17, 2026, and involve directly held shares.

Were the WST shares acquired by Chad Winters an open-market purchase?

No, the 149.684 WST shares were not an open-market purchase. They came from vested performance stock units for the 2023–2025 period, payable on February 17, 2026. The Form 4 classifies this as a grant or award acquisition at $0.00 per share.

Did Chad Winters sell WST shares on the market in this Form 4 filing?

The Form 4 shows a 50.579-share disposition at $243.19 per share, coded as “F.” This represents shares withheld to satisfy tax liabilities, not an open-market sale, meaning the company retained those shares for tax payment purposes.

How many WEST PHARMACEUTICAL SERVICES (WST) shares does Chad Winters own after these transactions?

Following the reported equity award and tax-withholding disposition, Chad Winters directly owns 1,462.103 shares of West Pharmaceutical Services common stock. This total reflects both the vested performance stock unit shares added and the small number withheld to cover taxes.

What is the significance of the 2023–2025 PSU performance period mentioned for WST?

The filing notes Winters’ new shares resulted from performance stock units tied to a 2023–2025 performance period. These PSUs vested at the end of that period and were delivered as common shares on February 17, 2026, reflecting his earned long-term incentive compensation.

How does the Form 4 classify Chad Winters’ WST share acquisition and disposition codes?

The acquisition of 149.684 WST shares is coded “A” for a grant or award, while the 50.579-share disposition is coded “F,” indicating payment of tax liability by delivering securities. Both transactions involve non-derivative common stock held directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 07:02 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winters Chad

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		149.684(1)	A	$0	1,512.682	D
Common Stock	02/17/2026		F		50.579	D	$243.19	1,462.103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown.

	/s/ Louis Lalli, as an agent for Chad Winters	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.